Kadmon Holdings Llc (KDMN) |
|
4.85 -0.12 (-2.41%)
|
01-20 23:18 |
|
Open: |
4.95 |
Pre. Close: |
4.97 |
|
High:
|
5.08 |
Low:
|
4.81 |
|
Volume:
|
2,494,357 |
Market Cap:
|
832M |
|
|
|
|
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.084 - 5.11 |
5.11 - 5.126 |
|
Low:
|
4.751 - 4.784 |
4.784 - 4.805 |
|
Close:
|
4.802 - 4.852 |
4.852 - 4.884 |
|
Technical analysis |
as of: 2021-01-20 4:49:10 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 6.04 One year: 7.05 |
| Support: |
Support1: 4.34 Support2: 3.83 |
| Resistance: |
Resistance1: 5.17 Resistance2: 6.04 |
| Pivot: |
4.27  |
| Moving Average: |
MA(5): 4.74 MA(20): 4.30
MA(100): 4.06 MA(250): 4.22 |
| MACD: |
MACD(12,26): 0.15 Signal(9): 0.06 |
| Stochastic oscillator: |
%K(14,3): 79.43 %D(3): 82.29 |
| RSI: |
RSI(14): 64.37 |
| 52-week: |
High: 5.50 Low: 2.30 Change(%): 8.3 |
| Average Vol(K): |
3-Month: 255347 10-Days: 422410 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.KDMN has closed below upper band by 11.1%. Bollinger Bands are 81% wider than normal. The large width of the bands suggest high volatility as compared to KDMN's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 15 Jan 2021
Steven Cohen Boosts Kadmon Holdings Stake - Yahoo Finance
Fri, 15 Jan 2021
Brokerages Anticipate Kadmon Holdings, Inc. (NASDAQ:KDMN) Will Announce Quarterly Sales of $490,000.00 - MarketBeat
Mon, 30 Nov 2020
Kadmon Holdings Inc (KDMN) Stock: Buy, Hold, or Sell? - InvestorsObserver
Fri, 20 Nov 2020
Is Kadmon Holdings Inc (KDMN) a Stock to Watch This Week? - InvestorsObserver
Mon, 09 Nov 2020
What is the Forecast Price for Kadmon Holdings Inc (KDMN) Stock? - InvestorsObserver
Mon, 26 Oct 2020
Kadmon Holdings (NYSE:KDMN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - Yahoo Finance
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
172 |
| Shares Float (M) |
133 |
|
% Held by Insiders
|
0.14 |
|
% Held by Institutions
|
96.54 |
|
Shares Short (K)
|
27,640 |
|
Shares Short P. Month (K)
|
29,460 |
Stock Financials |
|
EPS
|
-0.593 |
|
EPS Est This Year
|
-1.550 |
|
EPS Est Next Year
|
-1.750 |
|
Book Value (p.s.)
|
0.570 |
|
Profit Margin
|
|
|
Operating Margin
|
-739.60 |
|
Return on Assets (ttm)
|
-32.4 |
|
Return on Equity (ttm)
|
-83.8 |
|
Qtrly Rev. Growth
|
209.5 |
|
Gross Profit (p.s.)
|
0.022 |
|
Sales Per Share
|
0.070 |
|
EBITDA (p.s.)
|
-0.513 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-77 |
|
Levered Free Cash Flow (M)
|
-42 |
Stock Valuations |
|
PE Ratio
|
-8.18 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.51 |
|
Price to Sales
|
68.92 |
|
Price to Cash Flow
|
-10.77 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
